CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers
Figure 2.Validation of prognostic implications of CCL19 expression for OS in BRCA patients across independent cohorts. OS analysis of 1879 BRCA samples in total from independent cohorts in GEO database was performed.